FBLG News & Events

FibroBiologics announced that the first patients have been enrolled and dosed in the company's Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers.

FibroBiologics announced preclinical data from its CYPS317 program for psoriasis presented at the Society for Investigative Dermatology 2026 Annual Meeting, held May 13-15, 2026, in Chicago, Illinois. "Our preclinical data reinforce the significant potential of a cell-based therapeutic for psoriasis and the importance of targeted immune modulation," said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. "Our fibroblast spheroid-based therapeutics have demonstrated durable immunomodulation across several chronic disease models. We believe these findings meaningfully strengthen the foundation for CYPS317 as a differentiated therapeutic approach for patients living with psoriasis."

FibroBiologics announced a strategic expansion of its fibroblast-based platform to target Hantavirus. Building on existing preclinical work in treating acute respiratory distress syndrome, the major cause of lethality in COVID-19 patients, FibroBiologics is expanding its therapeutic platform to encompass Hantavirus pulmonary syndrome, which causes similar terminal lung damage and inflammatory cascade as severe COVID-related ARDS.

FibroBiologics announced preclinical results suggesting that topical treatment with human dermal fibroblast spheroids may reprogram the burn wound environment by dampening harmful inflammation, reshaping immune cell behavior, and reducing markers of scar-forming activity, within eight days of injury. "These preclinical results are an important validation of our strategy to broaden the FibroBiologics wound care platform beyond our core indications. Fibroblasts play an essential role in wound healing, and what we are seeing here suggests they may be uniquely positioned to address the pathological inflammation and scarring that define burn injuries," said Pete O'Heeron, founder and CEO.